Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, Jurado JC, Juric D, Mayer I, Ciruelos EM, Iwata H, Conte P, Campone M, Wilke C, Mills D, Lteif A, Miller M, Gaudenzi F, Loibl S. Rugo HS, et al. Among authors: wilke c. Ann Oncol. 2020 Aug;31(8):1001-1010. doi: 10.1016/j.annonc.2020.05.001. Epub 2020 May 13. Ann Oncol. 2020. PMID: 32416251 Free article. Clinical Trial.
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).
Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M; CT4002 study group. Awada A, et al. Among authors: wilke c. Ann Oncol. 2014 Apr;25(4):824-831. doi: 10.1093/annonc/mdu025. Ann Oncol. 2014. PMID: 24667715 Free article. Clinical Trial.
6q deletion is frequent but unrelated to patient prognosis in breast cancer.
Lebok P, Bönte H, Kluth M, Möller-Koop C, Witzel I, Wölber L, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E. Lebok P, et al. Among authors: wilke c. Breast Cancer. 2022 Mar;29(2):216-223. doi: 10.1007/s12282-021-01301-5. Epub 2021 Oct 8. Breast Cancer. 2022. PMID: 34625909 Free PMC article.
8p deletion is strongly linked to poor prognosis in breast cancer.
Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E. Lebok P, et al. Among authors: wilke c. Cancer Biol Ther. 2015;16(7):1080-7. doi: 10.1080/15384047.2015.1046025. Epub 2015 May 11. Cancer Biol Ther. 2015. PMID: 25961141 Free PMC article.
Partial PTEN deletion is linked to poor prognosis in breast cancer.
Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E. Lebok P, et al. Among authors: wilke c. BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3. BMC Cancer. 2015. PMID: 26672755 Free PMC article.
Cyclin D1 gene amplification is highly homogeneous in breast cancer.
Burandt E, Grünert M, Lebeau A, Choschzick M, Quaas A, Jänicke F, Müller V, Scholz U, Bokemeyer C, Petersen C, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Wilczak W. Burandt E, et al. Among authors: wilke c. Breast Cancer. 2016 Jan;23(1):111-119. doi: 10.1007/s12282-014-0538-y. Epub 2014 May 27. Breast Cancer. 2016. PMID: 24862872
Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer.
Lebok P, Huber J, Burandt EC, Lebeau A, Marx AH, Terracciano L, Heilenkötter U, Jänicke F, Müller V, Paluchowski P, Geist S, Wilke C, Simon R, Sauter G, Quaas A. Lebok P, et al. Among authors: wilke c. Mol Med Rep. 2016 Aug;14(2):1443-50. doi: 10.3892/mmr.2016.5430. Epub 2016 Jun 23. Mol Med Rep. 2016. PMID: 27357606 Free PMC article.
p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer.
Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, von der Assen A, Burandt E. Lebok P, et al. Among authors: wilke c. Oncotarget. 2016 Dec 6;7(49):81322-81331. doi: 10.18632/oncotarget.13227. Oncotarget. 2016. PMID: 27835607 Free PMC article.
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Lebok P, von Hassel A, Meiners J, Hube-Magg C, Simon R, Höflmayer D, Hinsch A, Dum D, Fraune C, Göbel C, Möller K, Sauter G, Jacobsen F, Büscheck F, Prien K, Krech T, Krech RH, von der Assen A, Wölber L, Witzel I, Schmalfeldt B, Geist S, Paluchoswski P, Wilke C, Heilenkötter U, Terracciano L, Müller V, Wilczak W, Burandt EC. Lebok P, et al. Among authors: wilke c. Aging (Albany NY). 2019 Sep 18;11(18):7796-7804. doi: 10.18632/aging.102287. Epub 2019 Sep 18. Aging (Albany NY). 2019. PMID: 31533087 Free PMC article.
619 results